ABSTRACT
We report a case of leiomyoma of the small bowel presenting with massive gastrointestinal (GI) bleeding that was diagnosed using dual-phase enhanced helical computed tomography (CT) in the preoperative period. A 68-year-old man was admitted to our hospital because of recurrent rectal bleeding. Gastroduodenoscopic and total colonoscopic examination results were negative; however, the patient continued to show bloody stool. Dual-phase enhanced helical CT was subsequently performed. CT revealed a hypervascular tumor, with evident extravasation of the contrast medium in the bowel lumen. We were successful in establishing the point of bleeding. Exploratory laparotomy was performed the same day. A solid round extraluminal mass was found at the proximal jejunum. Bleeding was observed over the serosal side of this tumor and segmental resection of the tumorous small intestine was performed. Pathologic examination revealed leiomyoma. Enhanced helical CT proved to be useful in localizing active GI bleeding.
Subject(s)
Gastrointestinal Hemorrhage/diagnostic imaging , Jejunal Neoplasms/complications , Leiomyoma/complications , Tomography, X-Ray Computed/methods , Aged , Gastrointestinal Hemorrhage/etiology , Humans , Jejunal Neoplasms/diagnostic imaging , Leiomyoma/diagnostic imaging , MaleABSTRACT
We conducted multi-site early phase II trial or oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer in cooperation with 19 institutes. Fifty mg/body of oral etoposide was administered daily for 21 consecutive days. Cycles were repeated every 28 days. In cervical cancer, 24 patients were enrolled and 17 of them were evaluated. The overall response rate including CR and PR was 23.5% (4/17). In ovarian cancer, 18 patients out of 21 enrolled were evaluated. The overall response rate was 16.7% (3/18). The primary toxicity observed was myelosuppression such as leukopenia, neutropenia, hemoglobin decrease and thrombocytopenia. Other adverse effects were anorexia, nausea, vomitting, fatigue, alopecia and stomatitis. From these results we concluded that oral etoposide administered for 21 consecutive days was effective against cervical cancer.
